Lexicon Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Lexicon Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 39.9% bzw. 49.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 47.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -100.1% betragen.

Wichtige Informationen

41.0%

Wachstumsrate der Gewinne

51.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	55.2%
Zukünftige Eigenkapitalrendite	-115.0%
Analystenabdeckung	Low
Zuletzt aktualisiert	27 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Aug 03

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Apr 25

Does Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?

Jan 04

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:LXRX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	127	-165	N/A	N/A	5
12/31/2025	53	-221	N/A	N/A	5
12/31/2024	12	-207	N/A	N/A	5
6/30/2024	4	-202	-196	-196	N/A
3/31/2024	2	-194	-186	-185	N/A
12/31/2023	1	-177	-162	-162	N/A
9/30/2023	1	-158	-135	-133	N/A
6/30/2023	0	-131	-112	-111	N/A
3/31/2023	0	-110	-99	-97	N/A
12/31/2022	0	-102	-90	-89	N/A
9/30/2022	0	-97	-90	-90	N/A
6/30/2022	0	-97	-88	-88	N/A
3/31/2022	0	-90	-87	-85	N/A
12/31/2021	0	-88	-88	-87	N/A
9/30/2021	0	-68	-100	-98	N/A
6/30/2021	7	38	38	-122	N/A
3/31/2021	16	-13	14	-146	N/A
12/31/2020	24	-59	17	-143	N/A
9/30/2020	33	-104	27	-133	N/A
6/30/2020	320	39	98	98	N/A
3/31/2020	321	85	117	117	N/A
12/31/2019	322	130	114	114	N/A
9/30/2019	330	164	111	111	N/A
6/30/2019	43	-89	-102	-102	N/A
3/31/2019	47	-101	-128	-127	N/A
12/31/2018	63	-121	-149	-149	N/A
9/30/2018	81	-126	-155	-155	N/A
6/30/2018	101	-129	-167	-167	N/A
3/31/2018	99	-130	N/A	-147	N/A
12/31/2017	92	-123	N/A	-185	N/A
9/30/2017	80	-133	N/A	-200	N/A
6/30/2017	81	-138	N/A	-202	N/A
3/31/2017	89	-141	N/A	-217	N/A
12/31/2016	79	-131	N/A	-176	N/A
9/30/2016	188	-22	N/A	139	N/A
6/30/2016	160	-22	N/A	149	N/A
3/31/2016	141	-11	N/A	165	N/A
12/31/2015	130	-5	N/A	185	N/A
9/30/2015	24	-94	N/A	-86	N/A
6/30/2015	24	-100	N/A	-81	N/A
3/31/2015	24	-98	N/A	-69	N/A
12/31/2014	23	-100	N/A	-76	N/A
9/30/2014	3	-115	N/A	-93	N/A
6/30/2014	3	-106	N/A	-96	N/A
3/31/2014	2	-109	N/A	-97	N/A
12/31/2013	2	-104	N/A	-91	N/A
9/30/2013	1	-112	N/A	-90	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: LXRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: LXRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: LXRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: LXRXDie Einnahmen des Unternehmens (49.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: LXRXDie Einnahmen des Unternehmens (49.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: LXRX wird voraussichtlich in 3 Jahren unrentabel sein.

Lexicon Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 41%

Price target increased by 13% to US$6.20

Consensus revenue estimates decrease by 44%, EPS upgraded

Consensus revenue estimates fall by 54%

Consensus revenue estimates decrease by 12%

Price target decreased by 7.2% to US$5.15

Recent updates

Lexicon Pharmaceuticals, Inc. to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

Lexicon Pharmaceuticals, Inc. Appoints Kristen L. Alexander as Its Principal Financial Officer

Lexicon Pharmaceuticals, Inc. Announces Post-Hoc Analysis of Phase 3 Data from the SCORED Clinical Trial

Consensus revenue estimates decrease by 41%

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Lexicon Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Lexicon Pharmaceuticals, Inc. Receives PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

Lexicon Pharmaceuticals, Inc. Publishes New Data Highlights Potential Cost-Savings of INPEFA®? (sotagliflozin) for Heart Failure

High number of new directors

Lexicon Pharmaceuticals, Inc. Announces Appointment of Mike Exton, Ph.D. as Chief Executive Officer

Lexicon Pharmaceuticals, Inc. Announces CEO Changes

Lexicon Pharmaceuticals, Inc. Announces That Data From it's RELIEF-DPN 1 Phase 2 Study of LX9211 Published in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Price target increased by 13% to US$6.20

Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much

New major risk - Shareholder dilution

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Lexicon Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024

Lexicon Pharmaceuticals, Inc., Annual General Meeting, May 10, 2024

Consensus revenue estimates decrease by 44%, EPS upgraded

Lexicon Pharmaceuticals, Inc. announced that it has received $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC, Artal International Management Sa, Artal International SCA, Artal Group S.A.

New major risk - Share price stability

Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Lexicon Pharmaceuticals, Inc. announced that it expects to receive $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC and other investors.

CEO & Director exercised options and sold US$161k worth of stock

Consensus revenue estimates fall by 54%

Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do

Lexicon Pharmaceuticals, Inc. Provides Business and Pipeline Update At 42nd Annual J.P. Morgan Healthcare Conference

Consensus revenue estimates decrease by 12%

Price target decreased by 7.2% to US$5.15

Lexicon Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain

Independent Director recently bought US$202k worth of stock

Consensus revenue estimates decrease by 31%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 30% to US$7.50

Lexicon Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Lexicon Pharmaceuticals, Inc. Appoints Lisa DeFrancesco as Head of Investor Relations and Corporate Strategy, Effective November 13, 2023

Lexicon Pharmaceuticals, Inc. Announces Data from Two Studies Demonstrating Positive Financial Impact of Inpefa (Sotagliflozin) to Be Presented At the Academy of Managed Care Pharmacy Nexus 2023 National Meeting

Independent Chairman of the Board recently bought US$1.1m worth of stock

Lexicon Pharmaceuticals, Inc. Announces the Retirement of Alan S. Nies from Board of Directors, Effective October 26, 2023

New minor risk - Share price stability

Lexicon Pharmaceuticals, Inc. Receives Preferred Formulary Status with Express Scripts for Medicare Patients

Lexicon Pharmaceuticals, Inc. to Present Study Results Relating to Sotagliflozin and Lx9211 At the 59Th Annual Meeting of the European Association for the Study of Diabetes

Consensus EPS estimates fall by 18%

Lexicon Pharmaceuticals, Inc. Announces Published Analysis of Sotagliflozin Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexicon Pharmaceuticals, Inc. Elects Diane E. Sullivan to Its Board of Directors

Lexicon Pharmaceuticals, Inc. Announces Resignation of Frank P. Palantoni from Board of Directors, Effective July 27, 2023

CEO & Director recently bought US$92k worth of stock

Lexicon Pharmaceuticals, Inc. Presents Study Results Relating to LX9211 and INPEFA (Sotagliflozin) At the American Diabetes Association’s 83rd Scientific Sessions

Lexicon Pharmaceuticals, Inc. Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure

Lexicon Pharmaceuticals, Inc. announced that it has received $72.21513 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. announced that it has received $62.795767 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. announced that it expects to receive $62.795767 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $62.204233 million.

Lexicon Pharmaceuticals, Inc. Announces Fda Approval of Inpefa™ (Sotagliflozin) for Treatment of Heart Failure

Consensus revenue estimates increase by 31%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Consensus EPS estimates fall by 13%

Full year 2022 earnings: EPS and revenues miss analyst expectations

CEO & Director exercised options and sold US$111k worth of stock

Does Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?

Lexicon Pharmaceuticals, Inc. Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia